We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA ISSUES FINAL REPORT ON DRUG MANUFACTURING REGULATIONS
FDA ISSUES FINAL REPORT ON DRUG MANUFACTURING REGULATIONS
September 29, 2004
The FDA this fall will start using a risk-based approach for prioritizing site inspections for certain pharmaceutical products, the agency announced yesterday in a final report on its current good manufacturing practice (cGMP) initiative.